In the Original Investigation, “Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial,”1 that was published online first on August 4, 2021, and in the September 2021 issue of JAMA Dermatology, the authors have reanalyzed the data after removing 19 patients from 1 center. The authors explain this removal, reanalysis, and corrections in a Letter.2 Corrections affect the Abstract; the Results section of the text; Tables 1, 2, and 3; Figures 1 and 2; the Visual Abstract; and eFigure 1 and eTables 4, 5, and 6 in Supplement 2. This article has been corrected online.
Reference
- 1.Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Blauvelt A. Reanalysis following removal of participants from 1 site in multicenter trial of upadacitinib vs dupilumab for atopic dermatitis. JAMA Dermatol. Published online February 14, 2024. doi: 10.1001/jamadermatol.2023.6198 [DOI] [PubMed] [Google Scholar]